EPW
BMRN icon

Evolve Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Evolve Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
4,456
-2,806
-39% -$154K 0.02% 815
2026
Q1 		$410K Sell
7,262
-360
-5% -$21K 0.02% 666
2025
Q4 		$453K Buy
+7,622
New +$415K 0.03% 569

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Evolve Private Wealth's BMRN Position: Q2 2026 in Review

Evolve Private Wealth reduced its BioMarin Pharmaceuticals (BMRN) stake by 39% in Q2 2026, selling an estimated $154K and leaving 4,456 shares worth $255K. The position accounts for 0.02% of the portfolio, ranked #815.

Evolve Private Wealth first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $453K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Evolve Private Wealth held 4,456 shares of BioMarin Pharmaceuticals worth $255K as of Q2 2026.
  • Evolve Private Wealth sold 2,806 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $154K.
  • BioMarin Pharmaceuticals made up 0.02% of Evolve Private Wealth's portfolio in Q2 2026, its #815 holding.
  • Evolve Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Evolve Private Wealth's BioMarin Pharmaceuticals position peaked at $453K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.